Camp4 Therapeutics (CAMP) CEO Josh Mandel-Brehm Buys Stock

What Happened
Josh Mandel-Brehm, Chief Executive Officer of Camp4 Therapeutics (CAMP), purchased 6,551 shares on August 3, 2026 at $1.65 per share in a private placement, for a total cash outlay of $10,809. This was a direct purchase (transaction code P), not a sale or option exercise — a straightforward equity purchase by an insider.

Key Details

• Transaction date: August 3, 2026; Filing date (Form 4): August 5, 2026 (appears timely under the two-business-day rule).
• Price and amount: 6,551 shares at $1.65 per share; total value $10,809.
• Transaction type: Purchase (private placement) — code P.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement dated September 9, 2025, as amended August 3, 2026, involving institutional investors and certain directors, employees, and consultants.

Context
This was a purchase in a private placement (insiders and institutional investors participated), which is generally a clearer expression of insider buying than routine sales. The filing shows a small-dollar purchase by the CEO; factual purchase activity can be of interest to investors but does not, by itself, indicate future company performance.